Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT06644313
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Potentially Resectable MET-altered Non-Small Cell Lung Cancer
Interventions
DRUG:
Vebreltinib
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China